Focused On-demand Library for DnaJ homolog subfamily B member 13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P59910

UPID:

DJB13_HUMAN

Alternative names:

Testis and spermatogenesis cell-related protein 6; Testis spermatocyte apoptosis-related gene 6 protein; Testis spermatogenesis apoptosis-related gene 3 protein; Testis spermatogenesis apoptosis-related gene 6 protein

Alternative UPACC:

P59910; B3LEP4; Q8IZW5

Background:

DnaJ homolog subfamily B member 13, known by alternative names such as Testis and spermatogenesis cell-related protein 6, plays a crucial role in the motility of sperm and cilia through its function in axonemal radial spoke complexes. This protein's involvement in the intricate processes of spermatogenesis and ciliary movement underscores its biological significance.

Therapeutic significance:

Linked to Ciliary dyskinesia, primary, 34, a disorder marked by motile cilia abnormalities leading to severe respiratory infections and bronchiectasis, DnaJ homolog subfamily B member 13 represents a promising target for therapeutic intervention. Understanding its role could open doors to potential therapeutic strategies.